Karl Deisseroth, Peter Hegemann and Georg Nagel have won the 2026 Nobel Prize in Physiology or Medicine for discoveries that transformed naturally occurring light-sensitive proteins into one of neuroscience’s most powerful experimental tools.
The Nobel Assembly at Sweden’s Karolinska Institute awarded the prize for “discoveries concerning light-gated ion channels and optogenetics”. The three scientists will share 12 million Swedish kronor, approximately $1.2 million, and will receive their medals and diplomas in Stockholm on December 10.
Their work made it possible for researchers to activate or silence carefully selected nerve cells using pulses of light. The technique, known as optogenetics, has given scientists a level of control over the living brain that conventional electrical stimulation and drugs could not provide.
The story began not with the human brain but with microorganisms that use light-sensitive proteins to respond to their environment. Hegemann and Nagel studied the green alga Chlamydomonas reinhardtii, which moves towards or away from light.
Their research helped identify and characterise proteins called channelrhodopsins. When exposed to particular wavelengths of light, these proteins open channels across a cell membrane and allow electrically charged particles, or ions, to pass through.
Nagel’s research group at the University of Würzburg describes how the scientists identified Channelrhodopsin-1 and Channelrhodopsin-2 in studies published in 2002 and 2003. The discoveries demonstrated that a single light-sensitive protein could directly control the electrical state of a cell.
That mechanism offered neuroscientists an extraordinary possibility. Neurons communicate through electrical impulses. If channelrhodopsins could be introduced into chosen neurons, researchers might be able to control those cells by illuminating them.
Deisseroth, a psychiatrist, bioengineer and neuroscientist at Stanford University, helped turn that possibility into a practical method for investigating the brain. His laboratory demonstrated that channelrhodopsins could be genetically introduced into mammalian neurons and used to make them respond to millisecond-scale flashes of light.
This combination of genetics and optics became known as optogenetics. Genetic targeting determines which cells receive the light-sensitive protein, while a laser or light-emitting device determines precisely when those cells are activated or suppressed.
The method allowed researchers to move beyond observing correlations between brain activity and behaviour. They could instead switch particular neural circuits on or off and examine what happened next.
Scientists have used optogenetics to investigate the circuits involved in movement, memory, fear, sleep, appetite, addiction and social behaviour. It has also become an important research tool in the study of Parkinson’s disease, epilepsy, depression, anxiety and other neurological or psychiatric conditions.
In animal experiments, researchers can activate selected neurons and observe immediate changes in movement or behaviour. They can also silence particular circuits to determine whether those cells are necessary for a memory, emotional response or physical action.
A scientific review indexed by the US National Library of Medicine describes optogenetics as providing fast, targeted control over precisely defined biological events, including activity inside freely moving mammals. Its speed and cellular precision distinguish it from electrodes, which may stimulate several types of nearby cells simultaneously.
The technique does not mean that doctors can simply treat human brain disorders by shining light into the skull. Most optogenetic experiments still require genetic modification of cells and the implantation of optical equipment, creating substantial clinical, ethical and regulatory barriers.
Researchers are nevertheless investigating whether related approaches could eventually restore vision, regulate abnormal brain activity or provide more selective treatment for neurological disease. Experimental work has already examined optogenetic techniques in retinal disorders, although widespread clinical use remains distant.
Each laureate contributed a different part of the scientific chain. Hegemann’s work helped explain how microorganisms sense and respond to light. Nagel helped establish the function of channelrhodopsins as directly light-controlled ion channels. Deisseroth and his collaborators converted those discoveries into a versatile system for controlling defined neural circuits.
The award recognises how fundamental research on algae became a technology used in neuroscience laboratories around the world. Proteins that evolved to help microorganisms navigate towards light now allow scientists to investigate how individual groups of brain cells produce movement, memory, emotion and behaviour.
The Nobel Prize therefore honours more than a single experiment. It recognises a series of discoveries that gave researchers the ability to interrogate the living brain with light, opening an entirely new way to examine how neural circuits work and what happens when they fail.
